DocStoX is a free AI-powered research platform for Indian equity markets, covering 6,800+ NSE & BSE stocks with prices, fundamentals, 326 financial ratios, shareholding, FII/DII flows, F&O, IPOs, a visual screener and AI stock scoring.

Yes. DocStoX has a free tier covering stock research, the screener, FII/DII data and educational guides, plus a free MCP API tier (50 tool calls/day) for AI assistants. A Pro plan adds higher limits and advanced features.

What data does DocStoX cover?

Every NSE & BSE listed stock (6,800+ instruments): EOD and intraday prices, income statement / balance sheet / cash flow, 326 ratios, quarterly shareholding, promoter pledge, mutual-fund holdings, FII/DII flows, F&O and option-chain data, analyst forecasts, IPOs, corporate actions and news.

Can AI assistants like ChatGPT or Claude use DocStoX data?

Yes. DocStoX runs a public Model Context Protocol (MCP) server at https://mcp.docstox.com/mcp with 39 tools, so Claude, ChatGPT, Cursor and other MCP clients can pull Indian market data directly. Setup and a free key are at https://docstox.com/mcp.

What is the PE ratio of Aspira Pathlab & Diagnostics Ltd?

Aspira Pathlab & Diagnostics Ltd has a price-to-earnings (PE) ratio of 2111.0 in the Healthcare Services sector.

What is the market capitalisation of Aspira Pathlab & Diagnostics Ltd?

Aspira Pathlab & Diagnostics Ltd has a market capitalisation of approximately ₹109 crore.

Aspira Pathlab & Diagnostics Ltd

540788·NSE·Healthcare Services

₹0.00▲ +0.00 (+0.00%)

Mkt Cap₹109 Cr

P/E2111.00

Vol—

Day—

52W49–136

Trading suspended. Not a live price.

Healthcare Services · Healthcare Service Provider

A steady, established business

O—H—L—PC—VWAP—VOL—

52W₹49.00

₹135.88

Snapshot

Key stats

Mkt Cap

₹109 Cr

P/E

2111.00Expensive

P/B

8.88

ROE

0.51%Weak

ROCE

17.37%Decent

52W High / Low

₹136 / ₹49

Div Yield

0.00%

EPS

₹2.01

Free — see our deterministic Fair Value range, business quality score, and the full bull/bear case for this stock.

Snapshot

Key statistics

P/E

2111.0Expensive

Below 15× is value territory; above 35× prices in strong growth

ROE

0.5%Weak

Above 15% is considered healthy for Indian equities

ROCE

17.4%Decent

Above 18% means capital is working hard

Debt/Eq

0.27Low

Below 0.5 is comfortable; above 1.5 strains the balance sheet

Mkt Cap

₹109 Cr

P/B

8.88

EPS

₹2.01

Div Yield

—

What changed

Recent changes

Promoters+28.19% stake last quarter

What matters

News impact

Today

Trading activity

Delivery %—

Turnover—

Trades—

VWAP—

Face value₹10.00

Market depth

Market depth available during market hours

Snapshot

Technical signals

Compounded annual growth

Growth (CAGR)

Revenue

+15.7%

+8.1%

10Y

—

Profit

—

+7.7%

10Y

+52.2%

EPS

—

10Y

—

Profile

Pros

Company has reduced debt.
Debtor days have improved from 42.1 to 25.3 days.
Promoter holding has increased by 28.2% over last quarter.

Watch-outs

Cons

Stock is trading at 9.06 times its book value
Though the company is reporting repeated profits, it is not paying out dividend
Company has low interest coverage ratio.
Company has a low return on equity of -2.31% over last 3 years.
Company might be capitalizing the interest cost
Earnings include an other income of Rs.0.52 Cr.

More Healthcare Services stocks · Healthcare Service Provider

Explore Aspira Pathlab & Diagnostics Ltd’s valuation

Free deep-dive tools · no sign-up

Fair ValueOur fair-value estimate, upside, and Bear/Base/Bull scenarios.Intrinsic ValueGraham & earnings-power intrinsic value with margin of safety.DCFDiscounted cash flow — free cash flow, growth, value per share.ValuationP/E, P/B, earnings yield and the full multiples picture.Financial RatiosProfitability, leverage and efficiency ratios at a glance.PeersHow it stacks up against its closest listed competitors.